Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you think insurance companies are your friend you are sadly mistaken. Ever had to fill out a prior authorization for a drug, even have insurance deny your care, ever have to get approval before you could get a procedure done, every have to use a formulary to pick the drug that your insurance company wants you to take. All of that is rationing care that your physician thinks you need. Why do you think there are patients still taking generic lovaza, because their insurance, much of it medicaid will not allow Vascepa yet.
I am not suggesting it for biotechs/pharmaceuticals. Some of these other things like insurance and pharmacy benefits administrators benefit by rationing healthcare, not providing it.
So much of healthcare spending is sucked out as profit and into shareholders hands by the Pharmacy Benefits Administrators, the Insurance Companies, the Distribution networks, and I hate to say this here, Big Pharma. I would add for profit hospitals but they don't make much money. Everyone calls this healthcare cost but it is capitalism at its best. As long as lobbyist and Wall Street run are government this is what we are going to get.
Our government needs to find ways to do some of this themselves or at least lower or limit the profit margins of these companies. I like what you are saying about Vascepa making a dent. On a similar note, Arena Pharmaceuticals has a new drug they just started testing that is a new approach for acute heart failure. They have great scientific discovery there and this could be epic in terms of cost savings to the overall healthcare system. I have placed a big bet on them as well for this drug and the rest of their pipeline.
My Affordable Care Act plan that is with Florida Blue Cross using Prime Therapeutic pharmacy benefits gets me Vascepa with my out of pocket for $9 for three months. Not a bad deal, although I pay a high price for the plan.
When large legislation gets put into law, things should be tweeked year after year to make them better.
Adjustments to plan costs in many parts of the country were never allowed That hasn't happened with the Affordable Care Act because the leadership of the Senate has decided they want to destroy it instead of improving it. Once we get leadership in place that wants to improve the healthcare of the American people instead of destroy anything that the prior Admin put in place it will improve and there will be more covered lives.
You have been here everyday. If you really have to ask that question you have not been paying attention.
Yes statins are considered essential health benefits.
This may appear political but its not.
US VP Pence Says HHS has designated coronavirus testing as an “essential health benefit,” HHS has Made Coronavirus Test An Essential Health Benefit To Ensure It Is Covered By Private Health Insurance, Medicare And MedicAid.
That is good and what needs to happen. It is ironic that they can do this because of ObamaCare. Well anyway...
What we as investors in AMRN want to hear is that Trump Administration has made Vascepa an essential health Benefit To Ensure It Is Covered By Private Health Insurance, Medicare And MedicAid.
Walk away from the message board and GO OUT THERE and tell your Senators and Representatives. You know the story of why it should be essential. Reductions in Heart Attached and Stroke etc... Go, be productive members of society.
I would say it will be for Cantor clients only. Cantor already came out with their price target so this should be a cheerleading rally. We should get some notes from Cantor afterwards.
Thank you for the link.
As long and scripts and revenue projections are rising we will not stall.
Cantor specialty pharma analysts to hold an analyst/industry conference call Biopharma & Specialty Pharmaceuticals Analyst Folkes, Chen and Kiml, along with Zachary Silbersher, Founding Partner of Kroub, Silbersher & Kolmykov, discuss the post-trial briefs for Amarin's Vascepa on an Analyst/Industry conference call to be held on March 5 at 1 pm.
Read more at:
https://thefly.com/landingPageNews.php?id=3044804
I know this latest drop in the stock priced scared a few people but there is no reason this stock is not going to be trending higher right back to 26. We are way below the moving averages here and will be trending higher over the next month or more.
Interest rates are going to be low for some time now. They do not need the money, so no reason to borrow it.
Once the loan is paid off, cash flow will pay for any operating or capital needs.
They haven't even started phase 3 trials, how will they come to market in 2023? Where are the placebo controlled trials? Without them, it will not come to market.
I don't think it will have much impact either in the long run.
However, now that testing is finally occurring some of those "flu" deaths are being reclassified as coronavirus deaths.
AMRN's debt will 100% be paid off this year. If you look at the balance sheet, 100% of the debt is short term.
As of yesterday, it is going on as planned. Organizers will do everything they can to mitigate risk....
I think most of the bright people here already know all of that but it is good for others to be reminded.
If you are interested you should look at the PHRMA discussions with the FDA regarding new indications and allowing time for the physicians to understand what is going on, before they advertise directly to patients.
Price normally should not matter during a buyout. At the same time, the buyout press release will often mention the premium above the most recent high to help justify it.
If you are that blind to what has been going on, I can't help you.
I'm done for the day, apologies to the board.
I was in Manatee County Florida yesterday hugging kids at a soccer game. Patient who has now tested positive with no known travel was in the hospital for five days before CDC allowed testing. Yes I'm blaming the guy who has indiscriminately been dismantling our government.
I know it doesn't fit your narrative but I never mentioned a budget. Do you really think a fully staffed competent CDC would have sent contaminated test kits all over the world? Leadership starts at the top. Don't get me wrong, I am glad the testing in the U.S. has finally started. It is just embarrassing that South Korea and China were able to get their testing up and running before the CDC. It is a good thing we got the Amarin legal documents this weekend. Is it true that Robinhood has been down all day? If it is true, I bet there will be people jumping out windows who stayed short over the weekend.
Cantor Speaks
dough
@semodough
·
2m
CANT Per $AMRN brief, "The undeniable fact is that prior art did not point to any particular avenue— whether niacin, fibrate, omega-3 fatty acid mixture or individual component [of which there are at least seven found in Lovaza], or entirely new agent—as most promising to reduce
Quote Tweet
dough
@semodough
· 6h
CANT $AMRN Post trial briefs for AMRN &generic filers of Vascepa were filed 2/28).read briefs positively for AMRN. arguments remain focused on obviousness and inducement. burden to invalidate all of AMRN's patents is on generics. They have to prove that USPTO did not do its job
dough
@semodough
·
3m
TGs in severely hypertriglyceridemic patients without raising LDL-C. This is the antithesis of obvious."reaffirm OW rating think peak sales potential of Vascepa is underappreciated. upward earnings revisions to levels not reflected in FactSet consensus expectations BUY PT 35
Cuts were targeted. Here is one that we wish we had back.
In 2005, during the H1N5 bird flu scare, the US Agency for International Development ran a program called Predict to identify and research infectious diseases in animal populations in the developing world. Most new viruses that impact humans — apparently including the one causing the Covid-19 disease — emerge through this route, so investing in early research is the kind of thing that, at modest ongoing cost, served to reduce the likelihood of rare but catastrophic events.
The program was initiated under George W. Bush and continued through Barack Obama’s eight years in office; then, last fall the Trump administration shut it down.
I am just responding to post that are on the board. I'm not a fan of the person you named that I shouldn't mention.
Gutting of the CDC is going to go down as a horrible move. Sending out contaminated test around the world is a major screw up for the CDC. This all reflect so poorly on the current administration. Shutting down flights is just part of the initial cover up.
He also talked about potentially partnering. We will know more at the end of March. This is all part of the negotiation process. WE DO NOT NEED YOU, but if you give us a very good deal we might consider partnering.
10 years of exclusivity in Europe plus patents that go beyond that. Patents that go beyond 10 years so because Amarin is not filing for older indications patents will include reduce-it patents and extend beyond 10 years. By holding off in Europe on Filing they got the Reduce-it patents filed and increased the value of the asset. Now that is some good news.
I guess you have not been paying attention to company announcements over the last week. Do you really think the stock market went down 13% because there have NOTbeen disruptions in supply chains, international travel and demand for oil?
https://www.earthobservatory.nasa.gov/images/146362/airborne-nitrogen-dioxide-plummets-over-china
Do some think this is just part of the hoax to bring down trump?
Thank you marjac, this makes so much more sense than the 100's of post discussing what might of, or probably maybe happened during settlement discussion.
We wouldn't have talked about this all weekend if it was priced in. The stock would not have dropped to this level if it were priced in. some of those who are risk averse have been out and will buy back in now that the documents are out and are favorable. Others will wait until Judge's ruling to buy back in. This ruling is the last unknown. Next things on the radar include sales to continue to grow and figure out who the EU partner will be. I think we will see a similar move as what you describe.
It is good this is not an initial launch and Amarin already has a sustainable run rate. It might also be a good thing that JL sandbagged guidance a little. I keep hearing in preparation for the virus, you should stock up on your medicines, so go get your three month update of Vascepa now.
Thanks to Hamoa and Marjac. Thank you both for easily understandable, well thought out posts.
How many times are you going to basically post the same thing to try and create some kind of hysteria?
The flu doesn't kill 8% of our patients over 70 and 15% of our 80 and over population. If it did that year over year, there would not be anyone left over 80 years old. It might not hurt the kids in the school but the kids in the school will still carry the virus and take it home to their patents and grandparents. Survival of the fittest. Good luck.
Just remember most lawyers do not take classes on patent law. Patent lawyers primarily come from law schools who are known for patent law specialties, They focus on patent law throughout the three years and take multiple patent law classes.
This is about supplements, i would ignore it.
We need to make sure to listen to competent qualified opinions regarding this. Not hysteria and emotion.
"This is a result of the one confirmed community acquired infection currently being treated at UC Davis I believe ( near Sacramento ) "
Not true. Patients under surveillance are all patients in California, not just related to this case. it includes patients who flew in initially from China and their relatives. it includes the people that the US flew back from Wuhan and the people who flew them back. It includes people who flew commercially from infected areas. They have not said how many may be related to this one patient.